The International Symposium ISyCatC III will focus on the targeting of  cathepsin C, a protease that activates most of tissue-degrading proteases during inflammatory diseases such as COPD, cystic fibrosis, bronchiectasis, granulomatosis with polyangiitis, inflammatory bowel diseases or rheumatoid arthritis. Cathepsin C thus appears as a potential therapeutic target to impair protease-driven tissue degradation in chronic inflammatory diseases.

This symposium will bring together for the third time the world leading specialists from academic labs and industry, working on cathepsin C and its target enzymes.  It will associate biochemists studying the functionality of cathepsin C, cell biologists studying its maturation and tissue localization, chemists developing specific cathepsin C  inhibitors and clinicians studying the pathologies in  which cathepsin C is directly or indirectly involved.

SYMPOSIUM ORGANIZED BY

 Chair: Dr Brice Korkmaz (INSERM/France)

 Scientific Committee: Dr Isabelle Couillin (CNRS/France), Dr Moez Rhimi (INRAe/France), Prof. Gilles Lalmanach (INSERM/France), Dr Aurélien Montagu (Studium/France), Dr Daniel Scherman (Foundation for Rare Disease/France), Prof. Rita Vanbever (Catholic University of Louvain), Dr Marcin Sienczyk (Wroclaw University of Science and Technology/Poland), Dr Rich Williams (Queen’s University Belfast/United Kingdom)

 Organization Committee: Roxane Domain, Catherine Douteau (INSERM/France), Valerie Hete (University of Tours)